Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of “Moderate Buy” by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.00.

A number of analysts recently weighed in on COYA shares. Lake Street Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Coya Therapeutics in a research report on Wednesday, November 5th. BTIG Research lifted their price target on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a report on Wednesday, February 18th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, January 8th.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently added to or reduced their stakes in COYA. XTX Topco Ltd bought a new position in shares of Coya Therapeutics during the 4th quarter valued at about $192,000. Occudo Quantitative Strategies LP purchased a new position in shares of Coya Therapeutics during the fourth quarter valued at $66,000. Millennium Management LLC acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at about $121,000. 683 Capital Management LLC acquired a new position in Coya Therapeutics in the 4th quarter valued at approximately $465,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Coya Therapeutics during the fourth quarter worth $128,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Price Performance

NASDAQ COYA opened at $4.98 on Friday. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $8.29. The business’s 50-day simple moving average is $4.93 and its 200-day simple moving average is $5.71. The firm has a market capitalization of $104.18 million, a P/E ratio of -4.49 and a beta of 0.27.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.